MK-1167 / Merck (MSD), Bionomics - LARVOL DELTA

A Clinical Trial of MK-1167 in Healthy Adults (MK-1167-010) (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting

Enrollment open

A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011) (clinicaltrials.gov) - P1 | N=16 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC

New P1 trial

MK-1167, a positive allosteric modulator of ?7 nicotinic cholinergic receptors: proof-of-biology, dose selection, and clinical trial design (CTAD 2025) - No abstract available

Clinical

A Clinical Trial of MK-1167 in Healthy Adults (MK-1167-010) (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC

New P1 trial

Merck Showcases Data for Alzheimer’s Disease Candidates MK-2214 and MK-1167 at CTAD 2025 (Merck (MSD) Press Release) - "Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced plans to present first-in-human data for MK-2214 and MK-1167 at Clinical Trials on Alzheimer’s Disease (CTAD) 2025 in San Diego, California from Dec. 1-4."

P1 data • P2 data • Alzheimer's Disease

A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) (clinicaltrials.gov) - P2 | N=350 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Trial completion date: May 2027 ➔ Jan 2027 | Trial primary completion date: May 2027 ➔ Jan 2027

Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck (GlobeNewswire) - "Neuphoria Therapeutics Inc...announced today that the Company is due to receive a $15 million milestone payment from Merck...The payment is triggered by the initiation, by Merck, of a Phase 2 clinical trial to evaluate the safety and efficacy of MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator (PAM), for the treatment of the symptoms of Alzheimer’s disease dementia (NCT06721156)...This $15M payment marks the second milestone achieved in the collaboration with Merck. Under the agreement, Neuphoria is eligible to receive up to $450M in additional milestone payments for certain development and commercial milestones associated with the progress of multiple candidates plus royalties on net sales of any licensed medicines."

Financing • Alzheimer's Disease • Dementia

A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) (clinicaltrials.gov) - P2 | N=350 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) (clinicaltrials.gov) - P2 | N=350 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC

New P2 trial • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

A Drug-Drug Interaction Study of Diltiazem and MK-1167 in Healthy Adult Participants (MK-1167-006) (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Merck Sharp & Dohme LLC

New P1 trial

A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004) (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Merck Sharp & Dohme LLC

New P1 trial

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007) (clinicaltrials.gov) - P1 | N=28 | Completed | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Completed

Trial completion • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007) (clinicaltrials.gov) - P1 | N=28 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Active, not recruiting

Enrollment closed • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007) (clinicaltrials.gov) - P1 | N=28 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | N=16 ➔ 28

Enrollment change • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007) (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007) (clinicaltrials.gov) - P1 | N=16 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC

New P1 trial • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia